MedBeats
Breaking news and information from the CDC, FDA and medical journals.
Coronavirus Infections
Latest update on COVID-19.
Read MoreLong-term Safety and Effectiveness of Natalizumab Treatment in Clinical Practice
Since the TOP 5-year interim analysis (December 2012), cohort size (6148 vs 4821), median exposure (3.3 vs 1.8 years) and median follow-up time (62 vs 26 months) have increased.
Read MoreFDA Approves New HIV Treatment for Patients with Limited Treatment Options
FDA approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies
Read MoreRivaroxaban in Peripheral Artery Disease after Revascularization
In patients with PAD who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or death from cardiovascular causes than aspirin alone.
Read MoreMultisystem Inflammatory Syndrome in U.S. Children and Adolescents
Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents.
Read MoreCKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties
HDL from CKD rabbits and patients on hemodialysis exhibited an impaired ability to inhibit platelet aggregation, suggesting that altered HDL properties may contribute to the increased cardiovascular risk in this population.
Read MoreFDA Approves First-Line Immunotherapy
FDA approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Read MoreTen-Year Risks of Recurrent Stroke, Disability, Dementia and Cost in Relation to Site of Primary Intracerebral Haemorrhage
Compared with non-lobar ICH, the substantially higher 10-year risks of recurrent stroke, dementia and lower QALYs after lobar ICH highlight the need for more effective prevention for this patient group.
Read MoreFDA Approves New Therapy for Dravet Syndrome
Fintepla (fenfluramine), a Schedule IV controlled substance approved by FDA for the treatment of seizures associated with Dravet syndrome in patients age 2 and older.
Read MoreA Randomized, Placebo-Controlled Trial of Emricasan in Patients With NASH and F1-F3 Fibrosis
Emricasan treatment did not improve liver histology in patients with NASH fibrosis despite target engagement and may have worsened fibrosis and ballooning.
Read More